Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 112.86% | 25.09% | 47.90% | -21.30% | -10.40% |
| Total Depreciation and Amortization | 0.00% | 40.80% | -0.79% | -9.35% | -3.47% |
| Total Amortization of Deferred Charges | 0.25% | 0.00% | -0.25% | -23.43% | 1.55% |
| Total Other Non-Cash Items | 1,007.34% | 1,031.58% | -101.95% | 3,996.00% | -100.61% |
| Change in Net Operating Assets | 158.24% | -263.47% | 21.44% | 128.00% | 137.05% |
| Cash from Operations | 138.82% | -103.70% | 59.92% | -10.46% | 11.95% |
| Capital Expenditure | -- | -- | -54.40% | -22.80% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -61.85% | -25.09% | 0.74% | 545.42% | 89.05% |
| Cash from Investing | -61.85% | -24.43% | 0.43% | 533.90% | 88.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -98.86% |
| Repurchase of Common Stock | 100.00% | -2,188.00% | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -680.00% | 33.33% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 99.89% | -- | 100.00% |
| Cash from Financing | -7,767.13% | -450.00% | 88.65% | -6,442.86% | -100.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -232.38% | -111.74% | 3,111.73% | 98.25% | -182.23% |